SCHEDULE 13D/A: Orbic North America Revises Sonim Technologies Acquisition Bid to $1.81 Per Share, Citing 'Value Destructive Actions'

Orbic North America, along with its affiliates, has submitted a revised non-binding proposal to acquire Sonim Technologies Inc. for $1.81 per share in cash, a 98.9% premium to Sonim's recent closing price, while criticizing Sonim's recent corporate actions.

Summary

• AJP Holding Company, LLC, Jeffrey Wang, Orbic North America, LLC, Ashima Narula, and Parveen Narula (the "Reporting Persons") have filed an Amendment No. 9 to their Schedule 13D regarding their beneficial ownership in Sonim Technologies Inc.
• Orbic North America, LLC submitted a revised non-binding proposal on May 16, 2025, to acquire Sonim Technologies Inc. for a cash purchase price of $1.81 per share.
• This revised offer represents a 98.9% premium to Sonim's common stock closing price of $0.91 on Nasdaq as of May 16, 2025.
• The proposal is contingent on standard terms and conditions and is valid until 5 pm EST on Monday, May 19, 2025.
• Orbic stated that Sonim's prior 'value destructive actions,' including adopting a poison pill, accelerating 733,157 equity awards, and issuing over 4.4 million shares and 550,000 warrants (resulting in over a 75% increase in outstanding shares), made their initial offer no longer viable and necessitated the lower revised price.
• The Reporting Persons collectively beneficially own a significant stake in Sonim, with Jeffrey Wang holding 19.1% (1,972,124 shares) and AJP Holding Company, Orbic North America, Ashima Narula, and Parveen Narula each holding 18.9% (1,946,345 or 1,947,345 shares, depending on the specific reporting person's calculation of shared dispositive power).
• The percentage ownership is calculated based on 10,301,563 shares of common stock outstanding, as reported in Sonim's Form 10-Q for the fiscal quarter ended March 31, 2025, and Form 8-K filed on May 16, 2025.

Sentiment

Score: 4

Explanation: The sentiment is mixed to slightly negative. While the offer presents a significant premium for shareholders, the underlying narrative from Orbic is highly critical of Sonim's management, accusing them of 'value destructive actions' that led to a lower revised offer and threatening a proxy contest. This indicates significant corporate conflict and potential instability.

Positives

• The revised proposal offers a significant 98.9% premium over Sonim's closing stock price on May 16, 2025, which could be attractive to existing shareholders.
• Orbic has secured financing support from Capstone Project Finance, LLC, indicating a viable funding source for the proposed acquisition.

Negatives

• Orbic's revised offer price is lower than its prior, unspecified offer, explicitly due to Sonim's alleged 'value destructive actions'.
• Sonim's actions, such as the adoption of a poison pill plan, acceleration of 733,157 equity awards, and issuance of over 4.4 million shares and 550,000 warrants, are characterized by Orbic as detrimental to shareholder value.
• The issuance of new shares and warrants has led to an over 75% increase in outstanding shares since Orbic's initial proposal, diluting existing shareholder value.

Risks

• The proposal is non-binding and subject to further due diligence, investment committee approval, and negotiation of definitive agreements, meaning the acquisition is not guaranteed.
• The offer has a short validity period, expiring on May 19, 2025, creating pressure for Sonim's Special Committee to respond quickly.
• If the business combination is not mutually agreed upon, Orbic intends to pursue a proxy contest at Sonim's 2025 Annual Meeting to install its own slate of directors, potentially leading to a disruptive corporate battle.
• Continued 'value-destructive measures' by Sonim could lead to further changes or withdrawal of Orbic's proposed offer.

Future Outlook

Orbic North America has stated that if a mutually agreeable business combination is not reached, it will continue to pursue its case directly to Sonim's stockholders at the 2025 Annual Meeting and seek to install its own slate of highly qualified candidates to Sonim's board of directors to unlock shareholder value and return Sonim to profitability.

Management Comments

• "The continuing deterioration of Sonim's stock price following these actions has demonstrated that such activities have been value destructive and not in the best interests of Sonim's stockholders."
• "Notwithstanding these facts, we are still interested in engaging Sonim to negotiate an agreeable business combination transaction, albeit at a lower price, that is reflective of Sonim's current financial performance."
• "We believe our offer represents an attractive offer for Sonim's stockholders, which needs to be seriously considered by the Special Committee."
• "Given the current state of Sonim business, we believe the Special Committee has a fiduciary duty to all Sonim's stockholders to take advantage of our meaningful proposal and to maximize stockholder value."
• "We, along with our financing sources, are prepared to expeditiously complete confirmatory due diligence and to prepare and negotiate a definitive business combination agreement."

Industry Context

This filing highlights ongoing shareholder activism and M&A activity within the technology sector, particularly concerning companies perceived as undervalued or mismanaged. The aggressive stance taken by Orbic, including the threat of a proxy contest, is a common tactic used by activist investors to pressure boards into strategic changes or sales. The criticism of 'poison pill' adoption and equity award acceleration reflects a broader investor concern about corporate governance practices that may entrench management at the expense of shareholder returns.

Corporate Governance

Related Party Transactions

• Jeffrey Wang, the sole manager of AJP Holding Company, LLC, directly holds 25,779 shares of common stock resulting from restricted stock units granted by Sonim Technologies, Inc. in accordance with its equity plan. This indicates a direct relationship between a reporting person and the issuer through equity compensation.

Stakeholder Impact

• Shareholders: Potential for a significant premium on their shares if the acquisition proceeds, but also risk of dilution from recent share issuances and potential for a prolonged proxy fight if the offer is rejected.
• Management/Directors: Accused of 'value destructive actions' by Orbic, facing pressure to accept the offer or a potential proxy contest, and have benefited from accelerated equity awards.
• Employees: Potential for changes in company direction, culture, or employment status if the acquisition is completed.
• Creditors: Potential impact on creditworthiness or debt covenants depending on the financing structure of the acquisition, though not explicitly detailed.

Next Steps

• Sonim's Special Committee is urged to seriously consider Orbic's proposal and negotiate a definitive business combination agreement.
• Orbic and its financing sources are prepared to expeditiously complete confirmatory due diligence.
• If no mutually agreeable business combination is reached by May 19, 2025, Orbic intends to pursue a proxy contest at Sonim's 2025 Annual Meeting.
• Orbic will seek to install its slate of qualified candidates to Sonim's board of directors to unlock shareholder value and return Sonim to profitability.

Key Dates

Recommendation

Keywords

Sonim Technologies, Orbic North America, Acquisition Proposal, Schedule 13D/A, Shareholder Activism, Takeover Bid, Corporate Governance, Poison Pill, Equity Awards, Stock Dilution, Capstone Project Finance, Proxy Contest